Resmed Inc Intrinsic Value Calculation – Czech National Bank Invests $3.80 Million in ResMed Inc
January 6, 2024
🌥️Trending News
RESMED ($NYSE:RMD): Czech National Bank has recently invested $3.80 million in ResMed Inc, a leading global provider of innovative medical equipment and solutions designed to improve the quality of life for people with sleep apnea, COPD, and other chronic diseases. The company’s products are designed to help improve respiratory health and sleep-disordered breathing, while providing patients with access to care anytime, anywhere. The investment from the Czech National Bank is a sign of confidence in the company and its ability to continue to develop innovative solutions. ResMed’s products are used by millions of people around the world, including those suffering from sleep apnea, COPD and other chronic respiratory diseases.
The company is committed to improving lives through the development of cutting-edge technologies that provide access to better quality of life. The $3.80 million investment from the Czech National Bank is a testament to ResMed’s success and its ability to make a positive impact on people’s lives. With this investment, ResMed will be able to further develop its products and services, while continuing to provide improved access to care for those with chronic diseases.
Market Price
On Tuesday, the Czech National Bank announced their investment of $3.80 million in ResMed Inc, a medical device company that specializes in providing innovative cloud-connected medical devices and digital health solutions. This investment comes as ResMed Inc’s stock opened at $171.3 and closed at $171.8, down slightly by 0.1% from their prior closing price of 172.0. ResMed Inc is known for developing and delivering clinically proven products and services focused on sleep apnea, COPD, asthma, and other chronic diseases.
The company has also been making strides in the digital health space, with its advanced cloud-connected medical devices and software solutions designed to provide a comprehensive view of a patient’s health. With the Czech National Bank’s backing, ResMed Inc is likely to continue its innovation and development of quality healthcare solutions for its customers. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Resmed Inc. More…
| Total Revenues | Net Income | Net Margin |
| 4.38k | 906.5 | 20.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Resmed Inc. More…
| Operations | Investing | Financing |
| 934.92 | -1.25k | 313.62 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Resmed Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 6.74k | 2.49k | 28.9 |
Key Ratios Snapshot
Some of the financial key ratios for Resmed Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 13.1% | 10.9% | 26.6% |
| FCF Margin | ROE | ROA |
| 18.1% | 17.4% | 10.8% |
Analysis – Resmed Inc Intrinsic Value Calculation
At GoodWhale, we have conducted an analysis of RESMED INC‘s fundamentals. We have estimated the fair value of RESMED INC’s share to be around $259.2, using our proprietary Valuation Line tool. Currently, RESMED INC’s stock is trading at $171.8, which implies that it is undervalued by 33.7%. Therefore, this presents an opportunity for investors to buy the stock at a discount. More…
Peers
ResMed’s competitors include Natus Medical Inc, Sanara MedTech Inc, and Avita Corp.
– Natus Medical Inc ($NASDAQ:SMTI)
As of 2022, Sanara MedTech Inc has a market cap of 227.36M and a Return on Equity of -22.91%. The company is a medical device company that develops and manufactures products for the treatment of chronic wounds and other conditions.
– Sanara MedTech Inc ($TPEX:4735)
Avita Corp is a biotechnology company that develops, manufactures, and markets products based on regenerative medicine. The company’s products are used to treat a variety of conditions, including burns, wounds, and skin diseases. Avita’s products are sold in over 30 countries worldwide. The company has a market cap of 1.21B as of 2022 and a return on equity of 9.62%.
Summary
RESMED Inc. (NYSE: RMD) is an attractive investment option for those looking to diversify their portfolio and capitalize on long-term growth. Recent reports suggest that the Czech National Bank has taken a stake in the company worth $3.80 million, indicating that they are confident in the potential of the stock. Analysts have praised the company’s diverse product offerings and strong competitive advantage.
The company has seen consistent sales growth year-over-year, and its net income has increased steadily over the past five years. The company also has a strong balance sheet with a solid cash position, making it well positioned to weather any economic downturn. With its low price-to-earnings ratio and reliable dividend yield, RESMED Inc. is an attractive choice for those looking to invest in a reliable and long-term growth stock.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
